Level Four Advisory Services LLC Sells 985 Shares of Vertex Pharmaceuticals Incorporated $VRTX

by · The Cerbat Gem

Level Four Advisory Services LLC lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 11.7% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 7,451 shares of the pharmaceutical company’s stock after selling 985 shares during the period. Level Four Advisory Services LLC’s holdings in Vertex Pharmaceuticals were worth $3,317,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. United Services Automobile Association bought a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $2,933,000. Lee Johnson Capital Management LLC bought a new position in Vertex Pharmaceuticals during the 2nd quarter worth approximately $721,000. Police & Firemen s Retirement System of New Jersey grew its position in Vertex Pharmaceuticals by 3.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company’s stock worth $17,378,000 after acquiring an additional 1,393 shares during the last quarter. Bailard Inc. increased its stake in Vertex Pharmaceuticals by 0.5% in the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock worth $16,983,000 after purchasing an additional 200 shares during the period. Finally, SteelPeak Wealth LLC bought a new stake in Vertex Pharmaceuticals in the second quarter valued at approximately $10,059,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ VRTX opened at $433.45 on Friday. The firm has a fifty day simple moving average of $415.59 and a two-hundred day simple moving average of $425.05. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.68. The firm has a market capitalization of $109.97 billion, a PE ratio of 30.98 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the previous year, the firm posted $4.38 EPS. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 53,604 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $440.72, for a total transaction of $23,624,354.88. Following the transaction, the chairman owned 24,026 shares in the company, valued at approximately $10,588,738.72. This represents a 69.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Canaccord Genuity Group dropped their price objective on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a research note on Wednesday, August 6th. Stifel Nicolaus dropped their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th. JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. HC Wainwright lowered their price objective on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating for the company in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald dropped their target price on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $491.95.

Get Our Latest Stock Report on Vertex Pharmaceuticals

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Further Reading

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).